Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameViridian Therapeutics, Inc (formerly Miragen Therapeutics Inc)
-
Registration countryUSA
-
IndustryMedical Services
-
М/S&P/F
*** /*** /***









